二甲双胍和罗格列酮治疗糖耐量减低的临床疗效观察

目的 观察二甲双胍和罗格列酮治疗糖耐量减低的疗效。方法 选择2006年8月～2008年3月我院内科门诊及住院44例，年龄在35～65岁初诊为糖耐量减低（空腹血糖在6.1～7.0mmol/L，口服75g葡萄糖后2h血糖在7.8～11.1mmol/L）人群，经运动干预、减轻体重、改变生活方式2个月后，仍达到或超过以上最低基线者，随机分为两组，分别给予口服二甲双胍缓释片500mg/d和罗格列酮胶囊4mg/d，疗程3个月。观察治疗前后体重、体重指数、血压、心率、糖耐量试验及血脂水平变化。结果 两组患者治疗后血糖明显降低，体重略有减轻，体重指数、血压、心率及血脂变化不显著。结论 二甲双胍和罗格列酮治疗糖耐量减低患者疗效可靠。

Clinical Observation of Metaformin and Rosiglitazone in Treatment of Impared Glucose Tolerance

Objective To observe the effect of metaformin and rosiglitazone in treatment of impared glucose tolerance. Methods 44 cases hospitalized in my courtyard internal medicine department from August 2006 to March 2008 were chosen, empty stomach blood sugar of first diagnosis for the sugar tolerance was between 6.1 and 7.0mmol/L,takes orally 75 gram glucose latter 2 hours blood sugars in 7.8 11. 1mmol/L, after movement intervention,lose weight, change llfe style in February, above still achieved or surpasses the lowest baseline, were divided into two groups stochastically,and were taken orally metaformin slow release piece 500mg/day and rosiglitazone separately the alkone capsule 4mg/day, the treatment course 3 months. Around observation treatment body weight, body weight index, blood pressure, heart rate, sugar tolerance experiment and blood fats level change. Results After treatment, the blood sugar of two groups reduced obviously, the body weight slightly reduced,the body weight index,the blood pressure,the heart rate and the blood fats change were not remarkable. Conclusion Metaformin and rosiglitazone has reliable curative effect in treatment of impared glucose tolerance.